top of page
  • FDA Announcements

RRMM:Daratumumab and Hyaluronidase-fihj (Darzalex Faspro) + Pomalidomide (Pomalyst) & Dexamethasone

FDA approved for RRMM: Daratumumab and Hyaluronidase-fihj (Darzalex Faspro) + Pomalidomide (Pomalyst) and Dexamethasone

Relapsed & Refractory Multiple Myeloma

FDA approves daratumumab and hyaluronidase-fihj with pomalidomide and dexamethasone for multiple myeloma

On July 9, 2021, the Food and Drug Administration approved daratumumab and hyaluronidase-fihj (Darzalex Faspro, Janssen Biotech, Inc.) in combination with pomalidomide and dexamethasone for adult patients with multiple myeloma who have received at least one prior line of therapy including lenalidomide and a proteasome inhibitor.

Efficacy was evaluated in APOLLO (NCT03180736), an open-label, active-controlled trial with 304 patients randomized (1:1) to Darzalex Faspro with pomalidomide and dexamethasone (Pd) vs Pd alone.


07/09/2021: FDA Approval




Commenting has been turned off.
Posts Archive
bottom of page